Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.
Adams R, Osborn G, Mukhia B, Laddach R, Willsmore Z, Chenoweth A, Geh JLC, MacKenzie Ross AD, Healy C, Barber L, Tsoka S, Sanz-Moreno V, Lacy KE, Karagiannis SN. Adams R, et al. Among authors: willsmore z. Oncoimmunology. 2022 Oct 3;11(1):2127284. doi: 10.1080/2162402X.2022.2127284. eCollection 2022. Oncoimmunology. 2022. PMID: 36211808 Free PMC article. Review.
BRAF inhibitors and their immunological effects in malignant melanoma.
Adams R, Coumbe JEM, Coumbe BGT, Thomas J, Willsmore Z, Dimitrievska M, Yasuzawa-Parker M, Hoyle M, Ingar S, Geh JLC, MacKenzie Ross AD, Healy C, Papa S, Lacy KE, Karagiannis SN. Adams R, et al. Among authors: willsmore z. Expert Rev Clin Immunol. 2022 Apr;18(4):347-362. doi: 10.1080/1744666X.2022.2044796. Epub 2022 Mar 3. Expert Rev Clin Immunol. 2022. PMID: 35195495 Review.
Enriched circulating and tumor-resident TGF-β+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs.
Harris RJ, Willsmore Z, Laddach R, Crescioli S, Chauhan J, Cheung A, Black A, Geh JLC, MacKenzie Ross AD, Healy C, Tsoka S, Spicer J, Lacy KE, Karagiannis SN. Harris RJ, et al. Among authors: willsmore z. Oncoimmunology. 2022 Jul 28;11(1):2104426. doi: 10.1080/2162402X.2022.2104426. eCollection 2022. Oncoimmunology. 2022. PMID: 35909944 Free PMC article.
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Willsmore ZN, et al. Eur J Immunol. 2021 Mar;51(3):544-556. doi: 10.1002/eji.202048747. Epub 2021 Feb 23. Eur J Immunol. 2021. PMID: 33450785 Free article. Review.
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. Willsmore ZN, et al. Front Immunol. 2021 Jan 25;11:622442. doi: 10.3389/fimmu.2020.622442. eCollection 2020. Front Immunol. 2021. PMID: 33569063 Free PMC article. Review.
Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.
Habib S, Osborn G, Willsmore Z, Chew MW, Jakubow S, Fitzpatrick A, Wu Y, Sinha K, Lloyd-Hughes H, Geh JLC, MacKenzie-Ross AD, Whittaker S, Sanz-Moreno V, Lacy KE, Karagiannis SN, Adams R. Habib S, et al. Among authors: willsmore z. Expert Rev Clin Immunol. 2024 Mar 27:1-17. doi: 10.1080/1744666X.2024.2326626. Online ahead of print. Expert Rev Clin Immunol. 2024. PMID: 38533720 Review.
11 results